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Quality control (QC) processes are being performed in the majority of clinical microbiology 
laboratories to ensure the performance of microbial identification and antimicrobial sus-
ceptibility testing by using ATCC strains. To obtain these ATCC strains, some inconve-
niences are encountered concerning the purchase cost of the strains and the shipping 
time required. This study was focused on constructing a database of reference strains for 
QC processes using domestic bacterial strains, concentrating primarily on antimicrobial 
susceptibility testing. Three strains (Escherichia coli, Pseudomonas aeruginosa, and 
Staphylococcus aureus) that showed legible results in preliminary testing were selected. 
The minimal inhibitory concentrations (MICs) and zone diameters (ZDs) of eight antimicro-
bials for each strain were determined according to the CLSI M23. All resulting MIC and ZD 
ranges included at least 95% of the data. The ZD QC ranges obtained by using the CLSI 
method were less than 12 mm, and the MIC QC ranges extended no more than five dilu-
tions. This study is a preliminary attempt to construct a bank of Korean QC strains. With 
further studies, a positive outcome toward cost and time reduction can be anticipated.
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To ensure test performance, microbial identification and per-
forming an antimicrobial susceptibility test (AST) require testing 
of standard quality control (QC) strains in clinical diagnostic mi-
crobiology laboratories [1-3]. Most clinical microbiology laborato-
ries conduct periodic internal QC tests using QC strains, which 
have established reproducibility and the QC ranges for regularly 
used antibiotics. The selection process for a QC strain is sophisti-
cated, especially for those of the AST QC strain that requires 
multiple considerations such as antibiotics, susceptibility testing 
methods, and QC ranges. The ATCC strains, which are typically 
shipped from the US, are commonly used as the QC strain in 
microbiology laboratories. The financial burden for purchasing 
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and time required for delivery of the ordered strains pose incon-
veniences to these laboratories. Although organizations such as 
the National Culture Collection of Pathogens (NCCP) in Korea 
are preserving many bacterial strains, these strains are rarely uti-
lized in the clinical microbiology laboratories, since their antimi-
crobial susceptibility data are unavailable. Hence, the objective 
of this study was to obtain preliminary AST QC ranges using bac-
teria preserved in the NCCP with a final goal of establishing a ref-
erence bank using local bacterial strains. 
 In the tier 1 step, three strains (Escherichia coli, Pseudomo-
nas aeruginosa, and Staphylococcus aureus), which are the 
most commonly used for QC in clinical microbiology laborato-
ries, were selected as target strains. Several isolates of each of 
the three strains, preserved in the NCCP in Korea, were evalu-
ated with multiple passages and multiple freeze/thaw cycles. 
Disk diffusion tests were performed according to the CLSI M23 
[2] by using the group A and B antibiotics suggested in the CLSI 
M100 [4]. The selected strains (E. coli NCCP 13894, P. aerugi-
nosa NCCP 12297, and S. aureus NCCP 11486), which exhib-
ited the most stable and legible results, were selected because 
they satisfied the following conditions: reproducibility and stabil-
ity through multiple passages, according to the CLSI M23 [2]. 
 The tier 2 steps were also performed following the guidelines 
in the CLSI M23 [2] with modification to the number of locations 
for which AST was conducted. To prepare inoculum suspen-
sions, fresh-grown strains selected in tier 1 testing were sent to 
the following seven independent laboratories in Korea: CHA 
Bundang Medical Center (Seongnam), Kangnam Sacred Heart 
Hospital (Seoul), Myongji Hospital (Goyang), National Health 
and Insurance Corporation Ilsan Hospital (Goyang), Neodin 
Medical Institute (Seoul), Severance Hospital (Seoul), and Yon-
gin Severance Hospital (Yongin). In each laboratory, inocula of 
each of the three strains were prepared to a turbidity of 0.5 Mc-
Farland standards and collected in the laboratory of Severance 
Hospital. Each inoculum suspension was then tested by using 
ten replicates of each of the selected strains on three dates, 
each with three separate media lots and two separate disk lots. 
The three media lots of Mueller-Hinton agar used for ASTs were 
manufactured by the following companies: BD Diagnostics 
(Sparks, MD, USA), Oxoid (Basingstoke, United Kingdom), and 
Bio-Rad (Mames-la-Conquette, France). The disk lots used for 
disk diffusion were manufactured by BD Diagnostics and Oxoid, 
and antibiotics were purchased from Sigma Chemical Company 
(St. Louis, MO, USA). Eight antibiotics, that is, piperacillin, 
ceftazidime, cefepime, aztreonam, imipenem, meropenem, ami-
kacin, and gentamicin, were tested for E. coli and P. aeruginosa. 
For S. aureus, the antibiotics penicillin, cefoxitin, vancomycin, 
teicoplanin, clindamycin, erythromycin, tetracycline, and cipro-
floxacin were tested. Agar dilution and disk diffusion tests were 
conducted according to the CLSI M7 [5] and the CLSI M2 [6], 
respectively. Proposed QC ranges of minimal inhibitory concen-
trations (MICs) and zone diameters (ZDs) were obtained on the 
basis of the CLSI M23 guideline by using means±standard de-
viations with adjustment to include at least 95% of the observed 
results [2]. The Range Finder method encompassing 95% of 
the value, that is, from the lower 2.5% of the distribution to the 
upper 97.5% of the value, was applied alternatively for compari-
son of the QC ranges calculated using the CLSI method [1].
 The proposed ranges of MIC (µg/mL) and ZD (mm) calcu-
lated for the selected E. coli are summarized in Table 1. For all 
tested antibiotics, the ranges of MIC calculated using both the 
CLSI and Range Finder methods fell within three twofold dilu-
tion ranges, and 100% of all MIC results were within the calcu-
lated QC ranges. The ranges of proposed ZD ranges calculated 
Table 1. Proposed quality control ranges of antimicrobial agents for selected Escherichia coli using disk diffusion and agar dilution tests
Antimicrobial agents
Agar dilution MIC* Disk diffusion zone diameter*
Proposed range (µg/mL) % of results in proposed range Proposed range (mm) % of results in proposed range
Piperacillin 1-4 100 23-32 (22-33) 96.4 (98.6)
Ceftazidime 0.25-1 100 25-33 (22-36) 95.7 (97.9)
Cefepime 0.03-0.125 100 27-37 (26-39) 95.2 (97.6)
Aztreonam 0.06-0.25 100 28-37 (25-39) 95.2 (98.3)
Imipenem 0.25-1 100 23-31 (21-34) 95.2 (98.1)
Meropenem 0.03-0.125 100 26-35 (25-37) 96.2 (98.1)
Amikacin 1-4 100 18-24 (17-26) 95.5 (98.3)
Gentamicin 0.25-1 100 16-25 (14-27) 96.0 (96.6)
*Range Finder results, if different, are in parentheses [1].
Abbreviation: MIC, minimal inhibitory concentration. 
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using the CLSI and Range Finder methods were 6-11 mm and 
9-15 mm, respectively [piperacillin (9; 11), ceftazidime (8; 14), 
cefepime (10; 13), aztreonam (9; 14), imipenem (8; 13), me-
ropenem (9; 12), amikacin (6; 9), and gentamicin (9; 13)], and 
95.2-96.4% and 96.6-98.6% of ZD results were within the QC 
ranges.
 The proposed ranges of MIC and ZD for the selected P. aeru-
ginosa are shown in Table 2. For all tested antibiotics, the pro-
posed ranges of MIC obtained by both the CLSI and Range 
Finder methods were within three twofold dilution MIC ranges, 
and 98.3-100% of all MIC results were within the calculated QC 
ranges. The ranges of proposed ZD ranges calculated using the 
CLSI and Range Finder methods were 5-9 mm and 8-14 mm, 
respectively, and 95.2-96.4% and 96.6-98.6% of ZD results 
were within the proposed QC ranges. 
 The range of MIC and ZD calculated for the selected S. au-
reus are summarized as proposed ranges in Table 3. For all 
tested antibiotics, 100% of the MIC results calculated by both 
the CLSI and Range Finder methods fell within the MIC ranges 
within three twofold dilution MIC ranges, except those of teico-
planin that was calculated by the CLSI method within four two-
fold ranges. The range of proposed ZD ranges calculated using 
the CLSI and Range Finder methods were 5-11 mm and 9-15 
mm, respectively, and 95.2-96.4% and 95.2-98.6% of results 
were within the proposed ZD ranges.
 Reliable and reproducible ASTs for clinically isolated microor-
ganisms are necessary to provide physicians with critical infor-
mation leading to the appropriate use of antimicrobials [7, 8]. To 
guarantee the results of ASTs, routine QC testing using QC 
strains is essential in clinical microbiology [2, 9]. When selecting 
the QC strain and determining the QC ranges, caution is required 
for the reproducibility of test results, performance for the objec-
tives of using the QC strains, stability of the strain, etc. [2]. Al-
though there are no consensus criteria concerning the ideal QC 
Table 2. Proposed quality control ranges of antimicrobial agents for selected Pseudomonas aeruginosa using disk diffusion and agar dilu-
tion tests
Antimicrobial agents
Agar dilution MIC* Disk diffusion zone diameter*
Proposed range (µg/mL) % of results in proposed range Proposed range (mm) % of results in proposed range
Piperacillin 4-16 98.7 25-33 (22-36) 95.7 (98.1)
Ceftazidime 4-16 98.7 24-32 (23-34) 98.3 (98.6)
Cefepime 4-16 100 20-27 (20-28) 98.1 (100)
Aztreonam 2-8 98.3 23-30 (21-32) 95.7 (99.1)
Imipenem 4-16 100 21-26 (19-27) 96.0 (98.1)
Meropenem 4-16 100 25-32 (24-33) 96.4 (99.5)
Amikacin 2-8 100 20-28 (19-30) 97.4 (98.8)
Gentamicin 1-4 100 16-25 (15-26) 97.4 (98.3)
*Range Finder results, if different, are in parentheses [1]. 
Abbreviation: MIC, minimal inhibitory concentration.
Table 3. Proposed quality control ranges of antimicrobial agents for selected Staphylococcus aureus disk diffusion and agar dilution tests
Antimicrobial agents
Agar dilution MIC* Disk diffusion zone diameter*
Proposed range (µg/mL) % of results in proposed range Proposed range (mm) % of results in proposed range
Penicillin 0.125-0.5 100 35-42 (31-45) 96.2 (98.6)
Cefoxitin 1-4 97.4 22-29 (18-33) 95.5 (96.9)
Vancomycin 0.5-2 100 15-20 (13-22) 96.4 (97.1)
Teicoplanin 0.25-2 (0.5-2) 100 (98.3) 12-21 (11-21) 95.2 (95.2)
Clindamycin 0.125-0.5 100 19-29 (17-32) 95.9 (97.9)
Erythromycin 0.5-2 100 22-30 (18-33) 95.5 (96.9)
Tetracycline 0.25-1 100 19-30 (18-32) 95.7 (98.6)
Ciprofloxacin 0.25-1 100 18-27 (15-30) 95.5 (97.6)
*Range Finder results, if different, are in parentheses [1].
Abbreviation: MIC, minimal inhibitory concentration.
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range of MIC and ZD for ASTs, excessively broad ranges of ZD 
and MIC are not recommended: a ZD range of >12 and twofold 
dilution rage of ≥5 for MIC [1]. The QC ranges deducted by our 
study satisfied this general concept: the ranges of MICs were 
within four twofold dilution MIC ranges, and the ranges of ZD 
calculated using the CLSI method were less than 12 mm.
 Limitations of this study include subculturing of the three 
strains and performing ASTs using the agar dilution method and 
disk diffusion method; furthermore, the results were interpreted 
in a laboratory, and the number of antimicrobials tested was 
limited to eight. Thus, the QC strains and obtained QC ranges 
are inadequate for immediate adoption by clinical microbiology 
laboratories owing to a possible bias of QC ranges and a lack of 
validation using automated microbroth dilution methods. How-
ever, standardized inoculum suspensions for the agar dilution 
method and disk diffusion test were prepared in seven indepen-
dent laboratories to reflect the inter-laboratory variations and 
were transported in cold storage within two hours to prevent 
bacterial overgrowth.
 In conclusion, this study is the first attempt to establish QC 
ranges for MIC and ZD of antimicrobial agents in Korea. The se-
lected QC strains show positive results for constructing a bank of 
QC strains for domestic clinical microbiology laboratories, though 
the strain and calculated QC ranges are inapplicable because of 
the limitations of this study. With further studies, a positive out-
come toward cost and time reduction can be anticipated.
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